Tran Thi Van Anh, Ha Thanh Hoa, Pham Quoc Tuan, Ngo Thi Sau, Do Mai Huong, Nguyen Van Thang, Tran Van Thao, Nguyen Thanh Hai, Dao Viet Hung

Main Article Content

Abstract

Abstract: Treatment of fungal infections is very difficult because of the limited therapeutic arsenal and the emergence of resistance to the two major antifungal classes: azoles and echinocandins. Consequently, finding new targets and new therapeutic strategies is a priority. The protein kinase Pkc1 of Candida albicans (CaPkc1), one of the key proteins involved in MAPK pathways, is described as a regulator of cell wall integrity during growth, morphogenesis, and response to cell wall stress. Therefore, the discovery of CaPkc1 inhibitory molecules can open up new and promising prospects in the development of new antifungal drugs that inhibit CaPkc1. In this study, we evaluated the CaPkc1 inhibitory activity of three benzofuro[3,2-d]pyrimidine derivatives at three different concentrations of 50 µM, 100 µM, and 150 µM. A concentration of 100 μM was optimal for CaPkc1 inhibitory activity with all three benzofuro[3,2-d]pyrimidine derivatives.


Keywords: Benzofuro[3,2-d]pyrimidine, CaPkc1, Candida albicans, antifungal activity.